BiotechTube

Famitinib capsules + Sunitinib Capsules

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Stromal Tumors

Trial Timeline

Sep 12, 2020 → Mar 25, 2022

NCT ID
NCT04409223

About Famitinib capsules + Sunitinib Capsules

Famitinib capsules + Sunitinib Capsules is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Gastrointestinal Stromal Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT04409223. Target conditions include Gastrointestinal Stromal Tumors.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04409223Phase 3Terminated

Competing Products

20 competing products in Gastrointestinal Stromal Tumors

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
52
Patritumab deruxtecanDaiichi SankyoPhase 1/2
41
DS-6157aDaiichi SankyoPhase 1
33
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
52
Naldemedine + PlaceboShionogiPhase 2
52
GemcitabineEli LillyPhase 1/2
41
OlaratumabEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 2
52
cetuximabEli LillyPhase 2
52
BBI503Sumitomo PharmaPhase 2
52
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
41
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
52
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
FamitinibJiangsu Hengrui MedicinePhase 2
52
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
77
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
77
EsomeprazoleAstraZenecaPhase 3
77
AZD2171AstraZenecaPhase 2
52
EsomeprazoleAstraZenecaPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85